Darbepoetin alfa biosimilar - CJ Healthcare

Drug Profile

Darbepoetin alfa biosimilar - CJ Healthcare

Alternative Names: CJ-40001; YLB217

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CJ HealthCare
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Anaemia

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Anaemia(In volunteers) in South Korea (IV, Injection)
  • 29 May 2018 YL Biologics plans a phase I trial for Anaemia in Japan (YL Biologics pipeline, May 2018)
  • 23 Jan 2018 Phase-III clinical trials in Anaemia in South Korea (SC) (CJ Healthcare pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top